The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1

(Article begins on next page)

05 May 2024

Accepted Article Preview: Published ahead of advance online publication

Leukemia

The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in Chronic Lymphocytic Leukemia cells through downregulation of Mcl-1

M Larrayoz, S J Blakemore, R C Dobson, M D Blunt, M J J Rose-Zerilli, R Walewska, A Duncombe, D Oscier, K Koide, F Forconi, G Packham, M Yoshida, M S Cragg, J C Strefford, A J Steele

This is a PDF file of an unedited peer-reviewed manuscript that has been accepted for publication. NPG are providing this early version of the manuscript as a service to our customers. The manuscript will undergo copyediting, typesetting and a proof review before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.

The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in Chronic Lymphocytic Leukemia cells through downregulation of Mcl-1

Marta Larrayoz[1], Stuart J Blakemore[1], Rachel C Dobson[1], Matthew D Blunt[1], Matthew JJ Rose-Zerilli[1], Renata Walewska[2], Andrew Duncombe[1], David Oscier[2], Kazunori Koide[4], Francesco Forconi[1,5], Graham Packham[1], Minoru Yoshida[3], Mark S Cragg[1*], Jonathan C Strefford[1*] and Andrew J Steele[1*]

[1]Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, United Kingdom.
[2]Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom
[3]Chemical Genomics Research Group, RIKEN Center for Sustainable Resource Science, Wako, Japan
[4] Department of Chemistry, University of Pittsburgh, Pittsburgh, PA15260, USA
[5]Cancer Sciences Unit, Cancer Research UK and NIHR Experimental Cancer Medicine Centres, University of Southampton, Southampton

[*]These authors contributed equally to the work

Corresponding author: Dr A Steele, Cancer Sciences Unit, Somers Building (MP824), Southampton General Hospital, Tremona Rd, Southampton, SO16 6YD, United Kingdom.
e-mail: a.steele@soton.ac.uk
Phone: (+44) 238 120 5170
Fax: (+44) 238 120 5152

Conflict of Interest
All authors declare no conflicts of interest.

Running title: Spliceostatin induces apoptosis by inhibiting Mcl-1 expression

Keywords; CLL; SF3B1; spliceostatin A; Mcl-1; ABT-199, Meayamycin B

Abstract

The pro-survival Bcl-2 family member Mcl-1 is expressed in chronic lymphocytic leukemia (CLL), with high expression correlated with progressive disease. The spliceosome inhibitor spliceostatin A (SSA), is known to regulate Mcl-1 and so here we assessed the ability of SSA to elicit apoptosis in CLL. SSA induced apoptosis of CLL cells at low nanomolar concentrations in a dose- and time-dependent manner, but independently of $SF3B1$ mutational status, $IGHV$ status and CD38 or ZAP70 expression. However, normal B and T cells were less sensitive than CLL cells ($p=0.006$ and $p<0.001$, respectively). SSA altered the splicing of anti-apoptotic $MCL-1_L$ to $MCL-1_s$ in CLL cells coincident with induction of apoptosis. Overexpression studies in Ramos cells suggested Mcl-1 was important for SSA-induced killing since its expression inversely correlated with apoptosis ($p=0.001$). IL4 and CD40L, present in patient lymph nodes, are known to protect tumor cells from apoptosis and significantly inhibited SSA, ABT-263 and ABT-199 induced killing following administration to CLL cells ($p=0.008$). However, by combining SSA with the Bcl-2/Bcl-x_L antagonists ABT-263 or ABT-199, we were able to overcome this pro-survival effect. We conclude that SSA combined with Bcl-2/Bcl-x_L antagonists may have therapeutic utility for CLL.

Introduction

Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of neoplastic lymphocytes in peripheral blood, bone marrow, lymph nodes and spleen. It is incurable without allogeneic transplantation and exhibits a high degree of heterogeneity in clinical course. Progressive disease is characterised by unmutated immunoglobulin heavy variable (*IGHV*) genes, ZAP70 and CD38 expression.[1] Genetic markers including deletions of 17p, 11q and 13q, trisomy 12 and *TP53* mutations[2-4] have been known to impact prognosis for some time, however with the emergence of next generation sequencing, a plethora of new genetic alterations have been identified including *NOTCH1* (10-15%)[5-8] and *SF3B1* (10-17%)[8-10] mutations which identify patients with progressive disease.[8]

SF3B1 is one of the proteins that make up the spliceosome and regulates excision of introns from pre-mRNA[11]. The catalytic core is made up of 5 small nuclear protein complexes (snRNP), U1, U2, U4, U5 and U6. SF3B1 belongs to the U2 snRNP complex implicated in constitutive and alternative splicing within eukaryotic cells. Mutations in *SF3B1* are generally missense mutations, predicted to generate altered splicing function.[8] They elicit changes in the RNA splicing profile in CLL cells and can affect important genes such as *FOXP1, ATM* and *TNIP1* amongst others.[9, 12] Therefore targeting the spliceosome may be a novel therapeutic approach for the treatment of CLL. Several compounds are available for this purpose,[13-16] including meayamycin B[17, 18] and the structurally related spliceostatin A (SSA).[16] SSA is a synthetically modified analog of the natural product FR901464,[19] while meayamycin B is prepared by total synthesis.[20] SSA binds to SF3B1 and possibly other members of the splicing factor 3 complex and targets normal splicing in the cell, promoting alternative gene splicing, accumulation of unspliced mRNAs in the nucleus and a decrease in translation.[16] Numerous transcripts have been shown to be down-modulated by SSA-altered splicing in HeLa cells.[21] Furthermore, work in neuroblastoma cells has highlighted the importance of the spliceosome in regulating the expression of the pro-survival Bcl-2 family member Mcl-1.[22]

In CLL, Mcl-1 expression correlates with stage of disease, lymphocyte doubling time, *IGHV* mutation status, ZAP70 positivity and CD38 expression.[23] Furthermore, the Mcl-1 expression level and Mcl-1:Bax ratio correlate with resistance to fludarabine and time to first treatment.[23] Mcl-1 may also be expressed to a greater extent in CLL lymph nodes compared with blood, where resistance to apoptosis is known to occur.[24] The emergence of Bcl-2 inhibitors such as ABT-263 and ABT-199 are showing considerable promise for the treatment of CLL, however these drugs are unable to inhibit

the anti-apoptotic effects of Mcl-1 conferred by the microenvironment,[25] thus identifying a known mechanism of resistance to these BH3-mimetics.[26-29] Several pan-Bcl-2 family inhibitors such as obatoclax, sabutoclax and AT-101 have been developed with low micromolar potency against Mcl-1. Obatoclax (a BH-3 mimetic) has been investigated in a phase I clinical trial for advanced CLL, but its effect was limited.[30] Studies on AT-101 with rituximab showed some efficacy, resulting in partial remissions.[31, 32] Therefore, there is a need to develop alternative Mcl-1 inhibitors perhaps in combination with Bcl-2/Bcl-x_L inhibitors.

In this study we showed that the SF3B1 splicing inhibitor SSA induced robust apoptosis in CLL cells whilst normal lymphocytes were significantly more resistant. Apoptosis was induced independently of *SF3B1* mutation status. SSA-induced apoptosis correlated with altered *MCL-1* RNA splicing and downregulation in Mcl-1$_L$ protein expression. IL4 and CD40L treatment conferred resistance to SSA-induced apoptosis; however, this resistance was reversed by combining SSA with the Bcl-2 family inhibitors ABT-199 or ABT-263. These data suggest that microenvironmental signals in the lymph node may make the CLL cells that reside there resistant to SSA. Therefore combining inhibitors of both Bcl-2/Bcl-x_L and Mcl-1 may be warranted for the treatment of CLL.

Methods

Patients

Diagnosis of CLL was according to the IWCLL-NCI 2008 criteria.[3] Fifty-nine samples were obtained from patients diagnosed with CLL at the Royal Bournemouth Hospital and Southampton General Hospital following ethical committee approvals (06/Q2202/30 and 228/02/t, respectively) under the declaration of Helsinki (Supplementary Table 1). Malignant cell isolation and the determination of their purity have been described previously.[33] Isolates typically contained >90% CD19$^+$CD5$^+$ cells. Normal B and T lymphocytes from peripheral blood were taken from healthy age-matched controls as previously described.[34] Mutational screening for *SF3B1* was carried out by Sanger sequencing as previously reported (Supplementary Table 2).[8]

Reagents and antibodies

Spliceostatin A was produced by Professor Yoshida (Riken Institute, Japan).[16] Meayamycin B was produced by the Koide group (University of Pittsburgh, USA).[20] ABT-199 and ABT-263 were purchased from Selleckchem (USA). Annexin V-FITC was produced in-house (Southampton CR-UK core protein production facility). Pan-caspase inhibitor Z-VAD.fmk (Z-VAD) was from Enzo Life Sciences (UK) and Q-VD-OPh was from Calbiochem (UK). Recombinant human IL4 and CD40L were

from R&D Systems (UK). Antibodies for flow cytometry and immunoblotting are detailed in Supplementary Table 3.

Cell culture

CLL cells were cultured as previously described.[35] The Burkitt's lymphoma cell lines Ramos and Raji were obtained from ECACC. Cells were maintained in RPMI1640 supplemented with 10% FCS, 2mM glutamine, penicillin/streptomycin and 1mM sodium pyruvate (Life Technologies, UK).

Cell viability assay

Cell death was measured by flow cytometry of Annexin-V-FITC and propidium iodide (PI) labelled cells as previously described.[36] Viable cells were negative for both Annexin-V and PI. Fifty percent inhibitory concentration values (IC_{50}) were measured using CalcuSyn software (Biosoft, UK). The combination effect of SSA and ABT-199 or ABT-263 was calculated by comparing the expected and observed survival, as previously described for CLL.[37, 38]

RT-PCR

Total RNA was isolated with the RNeasy mini kit (Qiagen, UK) as described by the manufacturer. Total RNA was reverse-transcribed with M-MLV enzyme (Promega, UK). Conventional PCR was performed for *DNAJB1*, *RIOK3*, *MCL-1*, *BCL-X* and *UBIQUITIN* (Supplementary Table 3) using the GoTaq Green Master Mix (Promega, UK). Real time PCR was performed on a LightCycler 480 (Roche, UK) using Syto9 (Life technologies, UK). Each sample was analysed in triplicate with *UBIQUITIN* as a house-keeping control. The relative gene expression was calculated by the $2^{-\Delta\Delta CT}$ method. Each sample was normalized to its non-treated matched sample.

Immunoblotting

Immunoblot analysis was performed as previously described.[36] Proteins were separated on 12% polyacrylamide gels (LifeTechnologies, UK). Blots were probed with primary antibodies (Supplementary Table 2) and secondary antibodies (Dako, UK). Blots were visualized with ChemiDoc-It Imaging System (UVP, UK) and densitometry performed with Image J.

Nucleofection

Nucleofection was performed with the Amaxa Cell Line Nucleofector Kit V (Lonza, UK), according to the manufacturer's instructions. Cells were nucleofected with the empty vector pcDNA3 (mock) or

pcDNA3-9E10-Mcl-1$_L$ plasmid, and were selected in complete media with 1mg/ml geneticin (Life Technologies, UK). Clones were evaluated for Mcl-1$_L$ overexpression after 14 days.

Statistical analysis

The normal distribution of the samples was tested by D'Agostino-Pearson test. Statistical differences between groups were evaluated by Student's t test or ANOVA when samples were normally distributed or by the Mann-Whitney U or Kruskal-Wallis test when samples were not. Correlation analysis was carried out using Pearson or Spearman test depending on the normality of the samples. Statistical analysis was performed using GraphPad Prism v6 (GraphPad Software Inc).

Results

SSA induces caspase-dependent apoptosis of CLL cells in a dose- and time-dependent manner

CLL samples (n=59) were treated with SSA (2.5-20nM) and cell death assessed by Annexin-V/PI staining and immunoblotting over 24h. SSA increased Annexin-V binding (Figure 1A) and cleaved caspase-3 and PARP (p89) (Figure 1B) within 24h at low nanomolar concentrations. CLL cell death was caspase-dependent since treatment with Z-VAD (Figure 1B-C) and QVD (Supplementary Figure 1A-B) significantly protected against SSA-induced cell death even at the highest concentrations (p=0.0027 and p=0.034 at 10nM and 20nM, respectively). Moreover SSA induced substantial apoptosis within 12-24h in a dose dependent manner (Figure 1D).

Sensitivity to SSA is independent of *SF3B1* mutational status

Due to the incidence of *SF3B1* mutations in CLL,[8, 10] we compared the effect of SSA on 13 patients carrying a mutation in this gene and 42 wild-type patients. The *SF3B1* mutations observed reflected the spectrum reported previously (Supplementary Table 2).[8] We confirmed that the splicing of *ATM*, *FOXP1* and *TNIP1* were altered in these samples as previously described[9, 12] (Supplementary Figure 2A-C). However, no significant difference between the mean SSA IC$_{50}$ of wild-type (5.5nM) and *SF3B1* mutated samples (4.9nM; p=0.516) was observed (Figure 2A). In addition, SSA appears equally effective at inducing substantial apoptosis independently of *IGHV* mutational status, ZAP70 or CD38 expression, and genetic abnormalities [del(13q), Tri12, del(11q) and del(17p)] (Figure 2B-E, Supplementary Figure 3A). To determine whether *SF3B1* mutations conferred resistance to other drugs, we treated 8 samples with *SF3B1* mutations and 18 wild-type patients with chlorambucil (CHL). Samples with *SF3B1* mutations were significantly (p=0.0016) more resistant to CHL than wild-type patients (Supplementary Figure 3B-C).

Normal B and T cells are less sensitive to SSA

Normal B ($CD19^+$) and T ($CD3^+$) lymphocytes from control age-matched healthy donors (HD) were more resistant to SSA than CLL cells, with an IC_{50} of 12.1nM (p=0.003) and 61.7nM (p<0.001), respectively (Figure 2F). We also selected three CLL samples in which the proportion of $CD5^+CD19^+$ (B-CLL) to total lymphocytes was lower than 60% cells and analysed the effect of SSA in the CLL cells ($CD19^+CD5^+CD3^-$), B-cells ($CD19^+CD5^-CD3^-$) and T-cells ($CD3^+CD5^+CD19^-$). As above, T cells from CLL patients were significantly more resistant than CLL cells (~60nM; p=0.029). However, we only observed a trend for increased resistance of normal B cells to SSA (16.9nM) compared to CLL (6.67nM) in these patients (Figure 2G).

SSA induces changes in *MCL-1* splicing

To assess the effect of SSA on splicing within CLL cells, we studied the genes *DNAJB1* and *RIOK3* in which other splicing inhibitors have been shown to induce intron retention (larger RT-PCR products). SSA induced a dose-dependent increase in the unprocessed mRNA species compared to the mature mRNA (Figure 3A). Therefore, SSA was shown to decrease the capability of the CLL cells to correctly process pre-mRNAs. The siRNA-mediated knockdown of SF3B1 induces changes in the splicing of *MCL-1* and *BCL-X* in solid tumors,[39] so, we investigated the effect of SSA on *MCL-1* and *BCL-X* in CLL cells. SSA decreased *MCL-1$_L$* and increased *MCL-1$_s$* isoforms in a dose-dependent manner even in the presence of Z-VAD (Figure 3B), confirming that the accumulation of *MCL-1$_s$* was not an indirect result of caspase cleavage and cell destruction. In contrast, *BCL-X* showed no altered splicing following SSA treatment (Figure 3C). SSA-induced altered splicing of *MCL-1* occurred in a time- and dose-dependent manner (Figure 3D-F), occurring as early as 6h after 5nM SSA administration and immediately prior to CLL apoptosis. Importantly, *MCL-1* splicing occurred to the same extent in both wild-type and *SF3B1* mutated samples (Supplementary Figure 4A-B). In addition, the changes in MCL-1 splicing were specific to SSA, as other drugs used to treat CLL did not affect this gene (Supplementary Figure 4C).

Altered *MCL-1* splicing reduces Mcl-1$_L$ protein expression

Next, we evaluated what impact altered splicing of *MCL-1* mRNA had on protein expression and whether SSA regulated expression of other Bcl-2 family members. SSA caused a marked reduction in Mcl-1$_L$ protein expression, which was equivalent in the presence of Z-VAD, indicating this decrease was not due to proteolytic cleavage after caspase activation. In contrast, Bcl-2 and Bcl-x$_L$ showed no consistent change in expression (Figure 4A). The pro-apoptotic BH3-only protein Puma decreased alongside Mcl-1$_L$ whereas Noxa increased in 5/7 samples. As such, Mcl-1$_L$ reduction was the only

Page | 7

consistent Bcl-2 family protein change observed and coincided with apoptosis, as measured by PARP cleavage (Figure 4A). A summary of the effect of SSA on Mcl-1$_L$ protein expression is presented in Figure 4B.The decrease in Mcl-1$_L$ protein started at 6h with 10nM SSA, coincident with the decrease in mRNA levels (Figure 4C). To indicate whether the reduction in Mcl-1$_L$ induced by SSA may be due to inhibition of SF3B1 we used a second inhibitor meayamycin B and showed similar results (Figure 4D). Finally, we correlated Mcl-1$_L$ and Bcl-x$_L$ expression at a basal level with sensitivity to SSA. Mcl-1$_L$ but not Bcl-x$_L$ expression inversely correlated with increased IC$_{50}$ values (p=0.045; Supplementary Figure 5A-C).

Overexpression of Mcl-1$_L$ protects Ramos cells from SSA-induced apoptosis

To confirm that Mcl-1$_L$ protein reduction was responsible for the SSA-induced apoptosis, we attempted to overexpress Mcl-1$_L$ directly. These studies are difficult to perform in CLL cells due to low transfection efficiency and/or high background apoptosis following nucleofection. Therefore, we undertook these studies in Ramos B cells in which we could more readily manipulate Mcl-1 protein expression. We first showed that SSA was able to induce apoptosis of Ramos cells with a comparable IC$_{50}$ to that of CLL cells (4.68nM) (Figure 5A-B), in a dose-, time- and caspase-dependent manner (Figures 5B-C). We also showed that SSA downregulated Mcl-1$_L$ expression in Ramos cells, akin to that in CLL (Figure 5A). We then nucleofected Ramos cells with plasmids containing a Myc-tagged Mcl-1$_L$ protein or the empty plasmid (mock) and selected three stable clones which overexpressed Myc-tagged Mcl-1$_L$ that is unable to be alternatively spliced by SSA (Figure 5D). Importantly, these clones were selected to reflect levels of ectopic Mcl-1$_L$ that could be considered physiological. Ramos cells which overexpressed Mcl-1$_L$ still underwent apoptosis but were significantly less sensitive to SSA induced killing at the concentrations investigated (Figure 5E-F). In contrast to CLL, SSA also strongly reduced Bcl-x$_L$ expression in Ramos cells, potentially explaining why they still undergo some apoptosis in the presence of sustained Mcl-1$_L$. To explore whether Bcl-x$_L$ levels could help explain differential sensitivity to SSA, a second B cell-line, Raji, was examined. In Raji cells, SSA again reduced Mcl-1$_L$ expression in a dose dependent manner but was unable to promote extremely high levels of apoptosis even at high doses (20-80nM). However, in contrast to Ramos cells Bcl-x$_L$ levels in Raji cells remained high in the presence of SSA, (Supplementary Figure 6), supporting the role of Bcl-x$_L$ in inhibiting SSA toxicity.

SSA-induced apoptosis is reduced in the presence of microenvironment support

Microenvironment signals are known to confer drug resistance to CLL cells and influence Mcl-1$_L$ expression.[36, 40-42] In order to analyse the potential effect of these signals on SSA-induced apoptosis,

we tried to mimic lymph node conditions *in vitro*. T cells are abundant in CLL lymph nodes,[43] therefore we treated CLL cells with CD40L plus IL4, mimicking T cell help. This combination caused the expected increase in phosphorylated STAT6, an indicator of IL4 signalling, phosphorylated IκBα, an indicator of NFκB activation and accumulation of the NFκB downstream targets Mcl-1 and Bcl-x$_L$ (Figure 6A). IL4/CD40L treatment doubled the expression of Mcl-1$_L$, whilst Bcl-x$_L$ increased further, up to ~3.5-fold compared to the control. This increase in Mcl-1$_L$ and Bcl-x$_L$ significantly correlated with resistance to SSA (p=0.008) (Figure 6B). However SSA was still able to promote *MCL-1* splicing (Figure 6C). These data again suggest that increased Bcl-x$_L$ expression by IL4/CD40L is associated with resistance to SSA.

SSA in combination with ABT-199 or ABT-263 synergises to overcome microenvironment signals

To confirm that the reduced sensitivity to SSA was a result of increased Bcl-x$_L$, we next evaluated SSA in combination with the BH3-mimetic ABT-263, which inhibits Bcl-2, Bcl-x$_L$ and Bcl-w but not Mcl-1, or ABT-199 which preferentially targets Bcl-2. These compounds alone or in combination were evaluated in CLL cells treated with (Figure 7) or without IL4/CD40L (Supplementary Figure 7). SSA, but not ABT-199 or ABT-263, induced a dose-dependent reduction of Mcl-1$_L$ whilst Bcl-2 and Bcl-x$_L$ expression did not significantly change (Figure 7A. Supplementary Figure 7A). In the absence of IL4/CD40L, all compounds induced efficient dose-dependent apoptosis (Supplementary Figure 7A-B). However, any combination effects were difficult to discern due to the substantial amount of apoptosis with the compounds alone (Supplementary Figure 7B). In contrast, following IL4/CD40L stimulation, CLL cells underwent significantly less SSA- and ABT-199-induced cell death, whilst becoming completely resistant to ABT-263 (Figure 7B). Nevertheless, the combination of SSA with ABT-263 or ABT-199 significantly augmented CLL apoptosis (Figure 7A-B). Using the fractional 2-drug analysis method previously described for CLL,[38, 44] we evaluated the synergistic interaction between SSA and ABT compounds. Values above the diagonal line represent additive interaction whilst those under the line are synergistic. Under basal conditions, the drug combinations presented additive or synergistic effects in most of the patients (Supplementary Figure 7C-D). In the presence of IL4/CD40L, a strong synergistic relationship was observed following treatment with SSA and ABT-199 (Figure 7C) or ABT-263 (Figure 7D). It was noteworthy that the combination of SSA and ABT-199 or ABT263 also presented marked synergistic effects on 17p deleted samples after IL4/CD40L stimulation (Supplementary Figure 8). These data suggest that SSA in combination with Bcl-2/Bcl-x$_L$ inhibitors may be a useful strategy for targeting cells receiving microenvironmental signals within the protective lymph node niche.

Discussion

Solid and haematological malignancies commonly overexpress anti-apoptotic Bcl-2 family members, allowing them to evade apoptosis.[45, 46] Whilst compounds have been developed to mimic BH3 proteins, many of these target Bcl-2, Bcl-x$_L$ and Bcl-w with little to no effect on Mcl-1.[45, 47] It is known that targeting all pro-survival members is critical for efficient apoptosis[48] and CLL is known to have elevated levels of Bcl-2, Bcl-x$_L$ and Mcl-1 in lymph nodes.[24] Furthermore, Mcl-1 expression is known to correlate with progressive disease, resistance to chemotherapy and time to first treatment[23], therefore overcoming Mcl-1 is likely to be critical for effectively treating CLL.

In this study, SSA, an analogue of FR901464 that inhibits the SF3B1 protein, induced altered splicing and down-regulation of Mcl-1$_L$, which was concordant with caspase-dependent apoptosis of CLL cells at low nanomolar concentrations. In agreement with the key role of Mcl-1 in regulating CLL survival, we saw an inverse correlation between Mcl-1$_L$ expression and sensitivity to SSA in CLL samples. Interestingly, 2- and 14-fold higher concentrations of SSA were required to kill normal B and T cells, respectively. This sensitivity profile indicates that B cells and particularly tumor B cells are more sensitive to spliceosome interference than T cells. The molecular basis behind this is unclear but since Mcl-1 and Bcl-x$_L$ are essential for T cell survival,[49] resistance may relate to Bcl-x$_L$ overexpression or differential splicing by SSA in B and T cells.

SSA-induced killing of CLL cells was independent of the mutational status of *SF3B1 and IGHV*, as well as, CD38 and ZAP70 expression. *SF3B1* mutations have been shown to be present at sub-clonal levels,[50] however all our *SF3B1* mutant samples exhibited deregulated splicing supporting the notion that the SF3B1 mutant protein in these cases has a functional impact. The equal sensitivity of CLL samples to SSA indicates a common mechanism of cell death irrespective of the size of the SF3B1 mutated clone within the population. Therefore further correlations between SSA sensitivity and *SF3B1* mutant sub-clonal levels from deep-sequencing data will be required to fully elucidate this relationship and these studies are ongoing. Furthermore, we showed that *SF3B1* mutated samples have a significantly greater IC$_{50}$ for chlorambucil than WT samples. These data suggest that *SF3B1* mutations may confer reduced sensitivity to drug induced apoptosis supporting previous reports with fludarabine.[51]

The binding of SSA to SF3B1 inhibits pre-RNA splicing[16] but also induces changes in alternative splicing.[52] We have demonstrated in CLL cells that SSA promotes alternative-splicing of *MCL-1*. Laetsch *et al*. observed similar results in neuroblastoma cell lines.[22] A reduction of SF3B1 protein by

Page | 10

siRNA in HeLa cells resulted in a similar increase in the $MCL-1_S:MCL-1_L$ ratio[39], however in neuroblastoma cell lines SF3B1 knockdown increased the production of $MCL-1_L$ modestly and $MCL-1_S$ markedly.[22] Together these data hint to a complex regulation of $MCL-1$ which likely varies in a cell and context dependent manner. In resting CLL cells, $MCL-1_L$ is the main isoform produced by alternative splicing. After SSA treatment, RT-PCR analysis indicated a preferential alternative splicing towards the $MCL-1_S$ isoform which resulted in a downregulation of the anti-apoptotic Mcl-1$_L$ protein. Previous studies have indicated that Mcl-1$_S$ might have pro- rather than anti-apoptotic properties.[53] We saw no evidence for the generation of mature Mcl-1$_S$ protein before or after SSA treatment in CLL or Ramos cells even in the presence of Z-VAD, suggesting that the Mcl-1$_S$ form is not stable and/or biologically functional in these cells. Supporting our hypothesis that Mcl-1$_L$ reduction is the primary reason for the apoptosis induced by SSA, we saw tight correlation between the reduction in $MCL-1_L$ transcripts, protein expression and apoptosis. Furthermore, overexpression of unspliceable Mcl-1$_L$ in Ramos cells partially protected from SSA-induced apoptosis. This incomplete protection may be due to the fact that SSA also downregulated Bcl-x$_L$, in Ramos cells (but not in CLL or Raji cells). Bcl-x$_L$ is not highly expressed in CLL cells in the blood, but is significantly expressed at higher levels in the lymph nodes.[24] In addition, our current observations using IL4/CD40L to mimic this microenvironment suggest that SSA alone may be less effective at treating CLL cells in the lymph node niche. These data are supported by results with Raji cells, which retained Bcl-x$_L$ expression and were relatively insensitive to SSA-induced apoptosis, although Mcl-1 was spliced and down-regulated. Another FR901464 analogue, meayamycin B, induced the same reduction on Mcl-1$_L$ expression (this study) and non-small cell lung cancer and head and neck cancer cell lines.[18, 54] Although, differential and off-target effects cannot be ruled out completely, the similar responses with two structurally different compounds suggests that cell death is regulated by altered $MCL-1$ splicing.

In our study, IL4/CD40L stimulation increased the expression of Bcl-x$_L$ and Mcl-1$_L$ and reduced the sensitivity of CLL cells to SSA. One explanation for this is that the induction of anti-apoptotic proteins was higher in IL4/CD40L-stimulated cells, indeed the levels of Bcl-x$_L$ appeared higher with IL4/CD40L treatment compared to the control. Several Bcl-2 inhibitors have been developed in the last 20 years, including the series of BH3-mimetics pioneered by Abbot.[55] ABT-737, ABT-263 and ABT-199 reflect the best developed exponents of this approach and have shown promising results as single agents or in combination with other cytotoxic agents.[56] The clinical trial of ABT-263 in CLL demonstrated rapid and profound reduction of CLL cells in the blood, whilst bone marrow biopsies showed evidence of residual CLL cells.[26] In that study, resistance to ABT-263 correlated with higher Mcl-1 expression

levels.[26] However, another study demonstrated that the resistance of CLL cells to ABT-737 was due to Bcl-2A1 and not Mcl-1 expression.[29, 57]

Under IL4/CD40L stimulation, ABT-199 or ABT-263 alone failed to induce significant apoptosis in CLL cells, whilst its combination with SSA produced a dramatic reduction in cell viability. Combinations of the BCR kinase inhibitors (ibrutinib or idelalisib) with Bcl-2 family inhibitors (ABT-199) have been proposed, since ibrutinib and idelalisib cause an efflux of CLL cells out of the lymph nodes into the blood where they can be readily killed by ABT-199. However, patients treated with BCR kinase inhibitors alone still have residual disease in their nodes. We therefore propose that a combination of ABT-199 with SSA may be a more successful approach for targeting residual disease in the lymph nodes in order to provide complete and durable responses for this currently incurable disease. Whilst costs preclude our investigation of SSA and ABT-199 or ABT-263 either alone or in combination *in vivo*, previous studies have been performed with meayamycin B and FR901464 alone and shown some antitumor effect *in vivo*, further suggesting their promise for use as effective new therapies.[59, 60]

Author contributions: ML, MY, MSC, JCS and AJS designed and analysed experiments and wrote the manuscript. ML, SJB, RD, MJJR and MDB performed experimental work. MY and KK synthesized SSA and meayamycin B, respectively. FF, RW, AD and DO obtained patient consent and analysed clinical data. DO, MY, KK and GP provided critical review.

Conflict of interests: The authors state that that there are no conflicts of interests.

Supplementary information is available at Leukemia's website

ACCEPTED ARTICLE PREVIEW

References

1.   Kay NE, O'Brien SM, Pettitt AR, Stilgenbauer S. The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. *Leukemia* 2007 Sep; **21**(9)**:** 1885-1891.

2.   Zenz T, Eichhorst B, Busch R, Denzel T, Habe S, Winkler D*, et al.* TP53 mutation and survival in chronic lymphocytic leukemia. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010 Oct 10; **28**(29)**:** 4473-4479.

3.   Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H*, et al.* Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. *Blood* 2008 Jun 15; **111**(12)**:** 5446-5456.

4.   Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C*, et al.* Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. *Blood* 2013 Feb 21; **121**(8)**:** 1403-1412.

5.   Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N*, et al.* Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. *Nature* 2011 Jul 7; **475**(7354)**:** 101-105.

6.   Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J*, et al.* Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. *J Exp Med* 2011 Jul 4; **208**(7)**:** 1389-1401.

7.   Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F*, et al.* Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. *Blood* 2012 Jan 12; **119**(2)**:** 521-529.

8.   Oscier DG, Rose-Zerilli MJ, Winkelmann N, Gonzalez de Castro D, Gomez B, Forster J*, et al.* The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. *Blood* 2013 Jan 17; **121**(3)**:** 468-475.

9.   Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L*, et al.* Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. *Nature genetics* 2012 Jan; **44**(1)**:** 47-52.

10. Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M*, et al.* Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. *Blood* 2011 Dec 22; **118**(26)**:** 6904-6908.

11. Kramer A. The structure and function of proteins involved in mammalian pre-mRNA splicing. *Annual review of biochemistry* 1996; **65:** 367-409.

12. Ferreira PG, Jares P, Rico D, Gomez-Lopez G, Martinez-Trillos A, Villamor N*, et al.* Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. *Genome research* 2014 Feb; **24**(2)**:** 212-226.

13. Kotake Y, Sagane K, Owa T, Mimori-Kiyosue Y, Shimizu H, Uesugi M*, et al.* Splicing factor SF3b as a target of the antitumor natural product pladienolide. *Nature chemical biology* 2007 Sep; **3**(9)**:** 570-575.

14. Albert BJ, Sivaramakrishnan A, Naka T, Czaicki NL, Koide K. Total syntheses, fragmentation studies, and antitumor/antiproliferative activities of FR901464 and its low picomolar analogue. *Journal of the American Chemical Society* 2007 Mar 7; **129**(9)**:** 2648-2659.

15. Gao Y, Vogt A, Forsyth CJ, Koide K. Comparison of splicing factor 3b inhibitors in human cells. *Chembiochem : a European journal of chemical biology* 2013 Jan 2; **14**(1)**:** 49-52.

16. Kaida D, Motoyoshi H, Tashiro E, Nojima T, Hagiwara M, Ishigami K*, et al.* Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. *Nature chemical biology* 2007 Sep; **3**(9)**:** 576-583.

17. Albert BJ, McPherson PA, O'Brien K, Czaicki NL, Destefino V, Osman S*, et al.* Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells. *Molecular cancer therapeutics* 2009 Aug; **8**(8)**:** 2308-2318.

18. Gao Y, Koide K. Chemical perturbation of Mcl-1 pre-mRNA splicing to induce apoptosis in cancer cells. *ACS chemical biology* 2013 May 17; **8**(5)**:** 895-900.

19.   Nakajima H, Sato B, Fujita T, Takase S, Terano H, Okuhara M. New antitumor substances, FR901463, FR901464 and FR901465. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. *The Journal of antibiotics* 1996 Dec; **49**(12)**:** 1196-1203.

20.   Osman S, Albert BJ, Wang Y, Li M, Czaicki NL, Koide K. Structural requirements for the antiproliferative activity of pre-mRNA splicing inhibitor FR901464. *Chemistry* 2011 Jan 17; **17**(3)**:** 895-904.

21.   Furumai R, Uchida K, Komi Y, Yoneyama M, Ishigami K, Watanabe H*, et al.* Spliceostatin A blocks angiogenesis by inhibiting global gene expression including VEGF. *Cancer science* 2010 Nov; **101**(11)**:** 2483-2489.

22.   Laetsch TW, Liu X, Vu A, Sliozberg M, Vido M, Elci OU*, et al.* Multiple components of the spliceosome regulate Mcl1 activity in neuroblastoma. *Cell death & disease* 2014; **5:** e1072.

23.   Pepper C, Lin TT, Pratt G, Hewamana S, Brennan P, Hiller L*, et al.* Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. *Blood* 2008 Nov 1; **112**(9)**:** 3807-3817.

24.   Smit LA, Hallaert DY, Spijker R, de Goeij B, Jaspers A, Kater AP*, et al.* Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. *Blood* 2007 Feb 15; **109**(4)**:** 1660-1668.

25.   Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MH*, et al.* Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. *Haematologica* 2015 Aug; **100**(8)**:** e302-306.

26.   Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL*, et al.* Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2012 Feb 10; **30**(5)**:** 488-496.

27.   Mazumder S, Choudhary GS, Al-Harbi S, Almasan A. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. *Cancer research* 2012 Jun 15; **72**(12)**:** 3069-3079.

28.   Al-Harbi S, Hill BT, Mazumder S, Singh K, Devecchio J, Choudhary G*, et al.* An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. *Blood* 2011 Sep 29; **118**(13)**:** 3579-3590.

29.   Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. *Blood* 2010 Apr 22; **115**(16)**:** 3304-3313.

30. O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ*, et al.* Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. *Blood* 2009 Jan 8; **113**(2)**:** 299-305.

31. Castro JE, Olivier LJ, Robier AA, Danelle J, Carlos SJ, Bi-Ying Y*, et al.* A phase II, open label study of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. *Blood* 2006 Nov; **108**(11)**:** 803A-803A.

32. Castro JE, Loria OJ, Aguillon RA, James D, Llanos CA, Rassenti L*, et al.* A phase II, open label study of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Evaluation of two dose regimens. *Blood* 2007 Nov; **110**(11)**:** 917A-918A.

33. Mockridge CI, Potter KN, Wheatley I, Neville LA, Packham G, Stevenson FK. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. *Blood* 2007 May 15; **109**(10)**:** 4424-4431.

34. Steele AJ, Prentice AG, Hoffbrand AV, Yogashangary BC, Hart SM, Lowdell MW*, et al.* 2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells. *Blood* 2009 Aug 6; **114**(6)**:** 1217-1225.

35. Steele AJ, Prentice AG, Hoffbrand AV, Yogashangary BC, Hart SM, Nacheva EP*, et al.* p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism. *Blood* 2008 Nov 1; **112**(9)**:** 3827-3834.

36. Steele AJ, Prentice AG, Cwynarski K, Hoffbrand AV, Hart SM, Lowdell MW*, et al.* The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment. *Blood* 2010 Nov 25; **116**(22)**:** 4569-4577.

37. Tonino SH, van Gelder M, Eldering E, van Oers MH, Kater AP. R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia. *Leukemia* 2010 Mar; **24**(3)**:** 652-654.

38. Chen R, Guo L, Chen Y, Jiang Y, Wierda WG, Plunkett W. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. *Blood* 2011 Jan 6; **117**(1)**:** 156-164.

39. Moore MJ, Wang Q, Kennedy CJ, Silver PA. An alternative splicing network links cell-cycle control to apoptosis. *Cell* 2010 Aug 20; **142**(4)**:** 625-636.

40. Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C*, et al.* Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. *Nature cell biology* 2012 Mar; **14**(3)**:** 276-286.

41. Grdisa M. Influence of CD40 ligation on survival and apoptosis of B-CLL cells in vitro. *Leukemia research* 2003 Oct; **27**(10)**:** 951-956.

42. Hayden RE, Pratt G, Roberts C, Drayson MT, Bunce CM. Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches. *Leukemia & lymphoma* 2012 Apr; **53**(4)**:** 537-549.

43. Patten PE, Buggins AG, Richards J, Wotherspoon A, Salisbury J, Mufti GJ*, et al.* CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. *Blood* 2008 May 15; **111**(10)**:** 5173-5181.

44. Tromp JM, Geest CR, Breij EC, Elias JA, van Laar J, Luijks DM*, et al.* Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2012 Jan 15; **18**(2)**:** 487-498.

45. Scarfo L, Ghia P. Reprogramming cell death: BCL2 family inhibition in hematological malignancies. *Immunology letters* 2013 Sep-Oct; **155**(1-2)**:** 36-39.

46. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011 Mar 4; **144**(5)**:** 646-674.

47. Anderson MA, Huang DC, Roberts AW. BH3 mimetic therapy: an emerging and promising approach to treating chronic lymphocytic leukemia. *Leukemia & lymphoma* 2013 May; **54**(5)**:** 909-911.

48. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE*, et al.* Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. *Science* 2007 Feb 9; **315**(5813)**:** 856-859.

49. Dzhagalov I, Dunkle A, He YW. The anti-apoptotic Bcl-2 family member Mcl-1 promotes T lymphocyte survival at multiple stages. *Journal of immunology* 2008 Jul 1; **181**(1)**:** 521-528.

50. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS*, et al.* Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. *Cell* 2013 Feb 14; **152**(4)**:** 714-726.

51. Te Raa GD, Derks IA, Navrkalova V, Skowronska A, Moerland PD, van Laar J*, et al.* The impact of SF3B1 mutations in CLL on the DNA damage response. *Leukemia* 2014 Nov 5.

52. Corrionero A, Minana B, Valcarcel J. Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. *Genes & development* 2011 Mar 1; **25**(5)**:** 445-459.

53. Bae J, Leo CP, Hsu SY, Hsueh AJ. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. *The Journal of biological chemistry* 2000 Aug 18; **275**(33)**:** 25255-25261.

54. Gao Y, Trivedi S, Ferris RL, Koide K. Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer cells. *Scientific reports* 2014; **4:** 6098.

55. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA*, et al.* An inhibitor of Bcl-2 family proteins induces regression of solid tumours. *Nature* 2005 Jun 2; **435**(7042)**:** 677-681.

56. Cragg MS, Harris C, Strasser A, Scott CL. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. *Nat Rev Cancer* 2009 May; **9**(5)**:** 321-326.

57. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ*, et al.* Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. *Blood* 2009 Apr 30; **113**(18)**:** 4403-4413.

58. Khaw SL, Merino D, Anderson MA, Glaser SP, Bouillet P, Roberts AW*, et al.* Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. *Leukemia* 2014 Jun; **28**(6)**:** 1207-1215.

59. Nakajima H, Hori Y, Terano H, Okuhara M, Manda T, Matsumoto S*, et al.* New antitumor substances, FR901463, FR901464 and FR901465. II. Activities against experimental tumors in mice and mechanism of action. *The Journal of antibiotics* 1996 Dec; **49**(12)**:** 1204-1211.

60. Osman S, Waud WR, Gorman GS, Day BW, Koide K. Evaluation of FR901464 analogues in vitro and in vivo. *MedChemComm* 2011 Jan; **2**(1)**:** 38-43.

Figure Legends

Figure 1. SSA induces apoptosis in CLL cells in a dose- and time-dependent manner.

CLL cells were incubated with vehicle control or 2.5-20nM SSA for 24h. (A) Apoptosis was quantified by Annexin V/PI staining and flow cytometry. (B) CLL cells were treated as above but in the presence or absence of Z-VAD.fmk. Immunoblotting was performed for cleaved caspase-3 and its substrate PARP with Hsc70 as a loading control. A representative blot of 6 patients is shown. (C) CLL cells (n=6) were incubated with SSA in the presence or absence of Z-VAD.fmk. Apoptosis was measured by Annexin V/PI and the number of viable cells remaining normalized to untreated control samples. (D) CLL cells were incubated with (5, 10 or 20nM) or without SSA for 6, 12 or 24h. Cell viability was assessed by Annexin V/PI (n=5) and normalized to untreated samples. Bars represent mean ± SD. *: P<0.05; **: P<0.01; ***: P<0.001.

Figure 2. Sensitivity of CLL and normal B and T cells to SSA-induced apoptosis
Cell viability assays were used to generate IC_{50} values for CLL samples treated with SSA (2.5-40nM SSA) for 24h. The IC_{50} values were plotted for (A) *SF3B1* mutated (n=13) and wild-type samples (n=42), (B) mutated-*IGHV* (M-CLL; n=26) and unmutated-*IGHV* (U-CLL; n=29), (C) ZAP70[+] (>30%) and ZAP70[-] (<30%), (D) CD38[+] (>30%) and CD38[-] (<30%), (E) genetic abnormalities del(13q) (n=21), Tri12 (n=5), del(11q) (n=11) and del(17p) (n=8) and wild-type (n=10). (F) Cell viability assays were performed in healthy age-matched donors (n=5). Apoptosis was evaluated by Annexin V/PI staining following gating on the normal B (CD19[+]) or T (CD3[+]) lymphocyte populations. A representative cohort of CLL samples is shown for comparison. (G) CLL, B and T cells from individual CLL patients (n=3) were compared in the same assay after staining with CD19, CD5 and CD3 to identify CLL (CD19[+]CD5[+]CD3[-]), B (CD19[+]CD5[-]CD3[-]) or T cells (CD19[-]CD5[+]CD3[+]). Lines represented mean ± SD. *: P<0.05; **: P<0.01; ***: P<0.001.

Figure 3. SSA treatment causes intron retention and modifies *MCL-1* RNA splicing in CLL cells.
(A) CLL samples were incubated with 2.5-20nM SSA for 24h and assessed for intron retention by PCR for *DNAJB1* and *RIOK3* in the presence (+RT) or absence (-RT) of reverse transcriptase (RT) (n=4). mRNA species with intron retention are highlighted by (»).*MCL-1* (B) and *BCL-X* (C) splice variants analysed by RT-PCR after SSA treatment in the presence or absence of Z-VAD.fmk (n=6). (D) The effect of SSA on *MCL-1* splicing was assessed in a dose- and time-dependent manner by RT-PCR (D) and real-time PCR (E-F). The relative expression of $MCL-1_L$ and $MCL-1_S$ was normalized to the control sample (0nM SSA) at each time point. All samples were assessed in triplicate and represent the mean ± SD. *UBIQUITIN* was used as house-keeping gene. *: P<0.05; **: P<0.01; ***: P<0.001.

Figure 4. SSA/Meayamycin B treatment reduces $Mcl-1_L$ protein expression
Immunoblotting was performed on CLL cells treated in a (A, B) dose- (24h) and (C) time-dependent manner (10nM) with SSA as indicated and various pro- and anti-apoptotic proteins investigated. CLL cells in (A) were also treated in the presence or absence of Z-VAD.fmk. (B) Quantitation of $Mcl-1_L$ protein expression normalised to Hsc70 in CLL samples treated with SSA (n=7); bars represent mean ± SD. (D) CLL cells were treated with Meayamycin B in a dose dependent manner and immunoblotting was performed for PARP and Mcl-1 . Hsc70 was used as a loading control. *: P<0.05; ***: P<0.001

Figure 5. $Mcl-1_L$ overexpression in Ramos cell lines induces resistance to SSA.
(A) Ramos cells were treated with SSA (1.25-10nM) for 24h in the presence or absence of Z-VAD.fmk (25µM) and PARP cleavage, $Mcl-1_L$ and $Bcl-x_L$ expression was investigated by immunoblotting. Hsc70 was used as a loading control for immunoblotting. (B) Ramos cells were incubated as above and viability assessed with Annexin V/PI by flow cytometry, plotted as the mean ± SD of 4 independent experiments. (C) Ramos cells were exposed to 5nM SSA for 6, 12, 18 and 24h. Data represent the mean ± SD of 4 independent experiments. (D) Ramos cells were nucleofected with an empty vector (Mock) or a vector containing the sequence for $Mcl-1_L$ tagged with myc (Mcl-1-tag myc). After selection, cellular extracts were subjected to immunoblot analysis for $Mcl-1_L$. (E) Annexin V/PI was

used to quantify cell viability following SSA treatment for 24h in Ramos cells overexpressing Mcl-1$_L$ or vector control. Raw data from a representative experiment is shown.(F) Summary of 3 independent experiments where data is represented as mean ± SD. **: P<0.01; ***: P<0.001 .

Figure 6. The effect of microenvironment signals on SSA-induced apoptosis.
CLL cells were treated with IL4 (10ng/ml) and/or CD40L (300ng/ml either alone or in combination, in the presence or absence of SSA (5-20nM). (A) Immunoblotting for PARP, phosphorylated STAT6 (pSTAT6), phosphorylated IκBα (pIκBα), Mcl-1$_L$, Bcl-x$_L$, Bcl-2 and Hsc70, as a loading control, were performed. (B) Annexin V/PI analysis was quantified following 24h of SSA treatment and the percentage of viable cells determined. (C) PCR was performed to investigate whether *MCL-1* underwent alternative splicing following 5-10nM SSA treatment in the presence of IL4 and CD40L alone or in combination. Mean values are shown. *: P<0.05; **: P<0.01.

Figure 7. SSA in combination with the Bcl-2 family inhibitors ABT-199 or ABT-263 augments apoptosis in CLL cells following IL4/CD40L treatment
CLL cells were treated with IL4 and CD40L for 6h. The cells were subsequently treated with SSA, ABT-199, ABT-263 or their combinations at a 1:1 ratio for 24h. (A) Immunoblotting was performed and analysed for the expression of PARP, Mcl-1$_L$, Bcl-x$_L$, Bcl-2 and Hsc70 as a loading control. (B) Annexin V/PI analysis was performed and the percentage of viable cells calculated. Data represent mean ± SD of seven independent experiments. (C) Synergistic interactions were evaluated at a 1:1 ratio between SSA and ABT-199 as indicated. (D) Synergistic interactions were evaluated at a 1:1 ratio between SSA and ABT-263. Points below the diagonal line represent synergistic interactions, above the line are additive. **: P<0.01; ***: P<0.001.

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

A

SSA (nM)   0 1.25 2.5   5   10   0 1.25 2.5   5   10   Z-VAD

PARP   113 kDa
                                                             89 kDa
Cleaved/Total PARP   .12 .20 .28 .68 .73   .24 .23 .20 .30 .68

Mcl-1$_L$ 40 kDa
Mcl-1$_L$/Hsc70   1.1 1.3 1.4 .94 .30   1.1 1.3 1.1 .99 .18

Bcl-x$_L$ 30 kDa
Bcl-x$_L$/Hsc70   .88 1.0 1.1 .65 .74   .92 1.1 .75 .41 .34

Hsc70   70 kDa

D

Mcl1$_L$-tag myc →   42 kDa
Mcl-1$_L$ →   40 kDa
Total Mcl-1$_L$/Hsc70   2.2 2.3 2.2 3.9 3.7 3.0

(WT Mock C1 Mock C2 Mcl-1 C1 Mcl-1 C2 Mcl-1 C3)

Hsc70   70 kDa

E

0 nM   2.5 nM   5 nM

WT: 70%   66%   9%
Mock: 77%   71%   18%
Mcl-1$_L$: 85%   67%   37%

□ 0 nM SSA
▨ 2.5 nM SSA
▨ 5 nM SSA

B

% Viable cells (normalized to control)

□ SSA
▨ SSA + Z-VAD

SSA (nM): 0, 2.5, 5, 10

*** at 5 and 10

C

% Viable cells (normalized to control)

□ SSA
▨ SSA + Z-VAD

Time (hours): 0, 6, 12, 18, 24

*** at 18 and 24

F

% Viable cells (normalized to control)

WT, Mock, Mcl-1

** and **

Figure 6

A

IL4	-	-	-	+	+	+	-	-	-	+	+	+
CD40L	-	-	-	-	-	-	+	+	+	+	+	+
SSA (nM)	0	5	20	0	5	20	0	5	20	0	5	20

PARP — 113 kDa / 89 kDa

Cleaved/Total PARP: .50 .54 .74 .39 .43 .69 .51 .51 .71 .35 .35 .61

pSTAT6 (Tyr641) — 110 kDa

pSTAT6/Hsc70: .0 .0 .0 .37 .38 .0 .0 .0 .0 .71 .66 .0

pIκBα (Ser32/36) — 40 kDa

pIκBα/Hsc70: .32 .44 .32 .52 .33 .24 .48 .62 .38 .71 .74 .47

Mcl-1$_L$ — 40 kDa

Mcl-1$_L$/Hsc70: .77 .93 .25 .88 1.0 .30 .69 .84 .17 1.4 1.4 .29

Bcl-x$_L$ — 30 kDa

Bcl-x$_L$/Hsc70: .34 .40 .37 .52 .53 .39 .45 .45 .32 1.1 1.0 .42

Bcl-2 — 28 kDa

Bcl-2/Hsc70: .80 .80 .81 .80 .76 .81 .75 .76 .70 .94 .88 .84

Hsc70 — 70 kDa

B

% Viable cells vs. NS, IL4, CD40L, IL4 + CD40L
Legend: 0 nM SSA, 5 nM SSA, 20 nM SSA
** , *

C

NT / IL4 / CD40L / IL4+CD40L
SSA (nM): 0 5 10 (each group)

MCL-1$_L$ — 444 bp
MCL-1$_S$ — 196 bp

UBIQUITIN — 165 bp

Figure 7